DEFA14A - Silo Pharma, Inc. (0001514183) (Filer)

DEF 14A - Silo Pharma, Inc. (0001514183) (Filer)

PRE 14A - Silo Pharma, Inc. (0001514183) (Filer)

424B5 - Silo Pharma, Inc. (0001514183) (Filer)

10-Q - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

8-K - Silo Pharma, Inc. (0001514183) (Filer)

SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to Silo's research and licensing partner Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," exclusively licensed to Silo by Columbia University. Columbia University recently received an Australian patent for the same invention. The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disord

SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo's research and licensing partner Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress" exclusively licensed to Silo by Columbia University. The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University. "Thi

SPC-15's intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced positive bioanalytical and safety/toxicology results for its U.S. Food and Drug Administration (FDA)-requested 7-day large animal safety study of its lead asset SPC-15. Silo CEO Eric Weisblum commented, "Overall, we believe the positive results of this study confirm that SPC-15's formulation and spray profile meets the safety standards for clinical trials. While the safety of the oral coun

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced completion of dosing in a U.S. Food and Drug Administration (FDA)-requested 7-day safety and toxicology large animal study of its lead asset SPC-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days. "Our novel PTSD drug candidate SPC-15 has already shown strong safety and therapeutic delivery, and we are confident about the final data results from our preclinical discovery program," said Eric Weisblum, CEO of Silo. "We rem

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 is a novel intranasal prophylactic targeting Post-Traumatic Stress Disorder (PTSD). The final drug studies ar

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The n

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).

SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled "Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders") that Silo licenses from Columbia University.  The to-be-issued patent will further strengthen Silo's IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected

SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset.  "The addition of Bitcoin to our treasury holdings is a strategic decision aimed at diversifying our assets to include a digital store of value with what we believe has significant upside potential," said Eric Weisblum, CEO of Silo. "Our purchase of Bitcoin is intended to provide a safeguard against inflation and is expected to position Silo to preserv

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

4 - Silo Pharma, Inc. (0001514183) (Issuer)

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin